ENANTA PHARMACEUTICALS, INC Lease Obligation Incurred
ENANTA PHARMACEUTICALS, INC (ENTA) reported Lease Obligation Incurred of $598.00 thousand for the 12-month period ending 2015-09-30, per its 10-K filed 2017-12-11.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2017-12-11
- ENANTA PHARMACEUTICALS, INC lease obligation incurred for the quarter ending 2015-09-30 was $423.00K.
- ENANTA PHARMACEUTICALS, INC lease obligation incurred for fiscal 2015 was $598.00K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|
| 2015-09-30 | $423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | $598.00K 10-K · filed 2017-12-11 | |
| 2015-06-30 | $175.00K 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |